Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters - 11/08/11
Doi : 10.1016/j.jaci.2011.01.070
Bradley Chipps, MD a 
, Sheldon Spector, MD b, Judith Farrar, PhD c, Warner Carr, MD d, Eli Meltzer, MD e, William Storms, MD f, Michael Kaliner, MD g, Allan Luskin, MD h, Donald Bukstein, MD i, John Oppenheimer, MD j, Brian Smart, MD k, Jenifer Derebery, MD l, Julia Harder, PharmD a, Mark Dykewicz, MD m, Michael Benninger, MD n
, Sheldon Spector, MD b, Judith Farrar, PhD c, Warner Carr, MD d, Eli Meltzer, MD e, William Storms, MD f, Michael Kaliner, MD g, Allan Luskin, MD h, Donald Bukstein, MD i, John Oppenheimer, MD j, Brian Smart, MD k, Jenifer Derebery, MD l, Julia Harder, PharmD a, Mark Dykewicz, MD m, Michael Benninger, MD n a Capital Allergy and Respiratory Disease Center, Sacramento, Calif
b California Allergy and Asthma Medical Group, Los Angeles, Calif
c Life Sciences Press, Washington, DC
d Allergy and Asthma Associates of Southern California, Mission Viejo, Calif
e Allergy and Asthma Medical Group and Research Center, San Diego, Calif
f William Storms Allergy Clinic, Colorado Springs, Colo
g Institute for Asthma and Allergy, Chevy Chase, Md
h Department of Medicine, University of Wisconsin, Madison, Wis
i Dean Clinic, Madison, Wis
j Pulmonary and Allergy Associates, Summit, NJ
k DuPage Medical Group, Glen Ellyn, Ill
l House Ear Clinic, Inc, Los Angeles, Calif
m Wake Forest University School of Medicine, Center for Human Genomics and Personalized Medicine Research, Winston-Salem, NC
n Head and Neck Institute, The Cleveland Clinic, Ohio
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: B. Chipps receives research support from Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Sunovion, and Merck-Schering; receives grants for educational activities from Alcon, Genentech, AstraZeneca, GlaxoSmithKline, and Novartis; has consultant arrangements with Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck-Schering, ISTA, Quintiles, and Dey; and is on the speakers’ bureau for Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck-Schering, ISTA, and Dey. W. Carr has consultant arrangements with MEDA, Alcon, and ISTA; receives research support from MEDA, Alcon, and ISTA; and serves on committees for the AAAAI and the ACAAI. E. Meltzer has consultant arrangements with and/or is on the advisory board for AdelphiEden, Amgen, Boehringer Ingelheim, Dey, Greer, ISTA, Johnson & Johnson, Meda, National Jewish Health, ONO Pharma, Rady Children’s Hospital San Diego, Sandoz, Stallergenes, Teva, Alcon, Kalypsys, Merck, Schering-Plough, and Sepracor; is on the speakers’ bureau for Alcon, GlaxoSmithKline, Merck, National Jewish Health, Nycomed, Sanofi-Aventis, Schering-Plough, and Sepracor; receives research support from Alexza, MAP, MedImmune, Alcon, Amgen, Astellas, Boehringer Ingelheim, Dey, Greer, ISTA, Johnson & Johnson, MEDA, Merck, Novartis, Sepracor, and Teva; has provided expert witness testimony in a case related to fexofenadine; is a fellow of the AAAAI and the ACAAI; and is a member of the World Health Organization. W. Storms receives research support from Alcon Labs, Amgen, Genentech, Meda, Merck, Novartis, Sunovion, and TEVA; has consultant arrangements with Alcon Labs, AstraZeneca, Genentech, Meda, Merck, Novartis, Sunovion, Strategic Pharmaceutical Advisors, TEVA, and the TREAT Foundation; and has served on speakers’ bureau for Alcon Labs, Genentech, Meda, Merck, Novartis, Sunovion, and TEVA. M. Kaliner has consultant arrangements with Alcon and Strategic Pharmaceutical Advisors; is on the speakers’ bureau for Meda and Ista Pharmaceuticals; has received research support from Schering-Merck, Alcon, and Meda; has provided legal consultation/expert witness testimony in cases related to nasal corticosteroids; and serves as historian for the World Allergy Organization. A. Luskin is on the advisory board for Merck, Genentech, Sunovium, and Ista and has consultant arrangements with Merck, Genentech, TEVA, Sunovium, and Ista. D. Burkstein is on the speakers’ bureau for Merck, AstraZeneca, Novartis, Meda, and Alcon and receives research support from Novartis and GlaxoSmithKline. J. Oppenheimer has consultant arrangements with AstraZeneca, GlaxoSmithKline, and Merck; receives research support from Novartis, Merck, and GlaxoSmithKline; and has provided legal consultation/expert witness testimony in cases related to medical malpractice defense. B. Smart is on the speakers’ bureau for AstraZeneca and GlaxoSmithKline and is a speaker/officer for the AAAAI. J. Derebery is on the advisory board for Meda Pharmaceuticals, Alcon Laboratories, Merck, Sonitus Hearing Aid Research, and Strategic Pharmaceutical Advisors; is on the speakers’ bureau for Meda, Alcon, and Merck; receives research support from the Coulter Foundation, Otonomy Inc, Sonitus Inc, Alcon, and Phonak/Sonova; has provided legal consultation/expert witness testimony in cases related to Allergy Immunotherapy; and is on the board of directors for Epic Hearing Healthcare and Sonitus Hearing Aid Research. M. Dykewicz receives travel support from Merck and is vice chair of the Rhinitis-Sinusitis Committee for the American College of Allergy, Asthma, and Immunology. M. Benninger has consultant arrangements with Alcon and Merck. The rest of the authors have declared that they have no conflict of interest. |
© 2011
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 127 - N° 6
P. 1640 - juin 2011 Retour au numéro
Article précédent
- Reply
- Charles E. Reed
- Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines
- Sheldon Spector, Dana Wallace, Richard Nicklas, Jay Portnoy, Joann Blessing-Moore, David Bernstein, Linda Cox, John Oppenheimer, David Lang, Diane Schuller, Christopher Randolph, Stephen Tilles, David Khan, In cooperation with Mark Dykewicz, MD
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?